Bing Ma

Jan 13, 2025 | onlinelibrary.wiley.com | Jiaming Zhang |Linlin Duan |Wei Zhang |Bing Ma

Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Sep 23, 2023 | biorxiv.org | Bing Ma |Madison Bailey |Suchitra Kamle |Gail Schor

AbstractNon-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. In NSCLC, 10-20% of Caucasian patients and 30-50% of Asian patients have tumors with activating mutations in the Epidermal Growth Factor Receptor (EGFR). A high percentage of these patients exhibit favorable responses to treatment with tyrosine kinase inhibitors (TKI). Unfortunately, a majority of these patients develop therapeutic resistance with progression free survival lasting 9- 18 months.